Ursula A. Matulonis, MD
Medical Director and Program Leader, Medical Gynecologic Oncology Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Matulonis is Medical Director and Disease Center Leader of the Medical Gynecologic Oncology Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.  She also is the interim director of the Susan F. Smith Center for Women’s Cancers at Dana-Farber. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in the genetic changes in ovarian cancer and how that can lead to rationale drug development and selection. 

Dr. Matulonis is Principal Investigator (PI) of several therapeutic clinical trials and translational studies for ovarian cancer. She is the overall PI on a Program Project Development Grant funded by the Ovarian Cancer Research Foundation entitled “Rational Combinations of Novel Biologic Agents for Ovarian Cancer Therapy.”  She is the PI on the project “Genetic Similarities between Serous Ovarian Cancer and Triple-Negative Breast Cancer” funded by the Breast Cancer Research Foundation. Dr. Matulonis serves on the National Comprehensive Cancer Network Recommendation and Guideline committee for ovarian cancer, the Massachusetts ovarian cancer Task Force, the Gynecologic Oncology Group ovarian committee, the National Cancer Institute Ovarian Cancer Task Force, the Scientific Advisory Board of the Ovarian Cancer Research Foundation, the Scientific Board of the Clearity Foundation, and is Medical Director and a board member for the non-profit organization Ovations for the Cure.  She is a recipient of the Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, the Leonard P. Zakim Patient Advocacy Award, and the Susan M. Love Award from Fenway Health.

After receiving her medical degree from Albany Medical College in Albany, New York, she completed an internship and residency at the University of Pittsburgh in Pittsburgh, Pennsylvania, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute.

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron and Seagen. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers bureau for ONC Live and Curio Science. 

Authors/Presenters:
Ursula Matulonis, MD–has disclosed that she is a consultant for AstraZeneca, Merck, NextCure, and Novartis. He receives financial or material support from DSMB and Symphogen. 

Angeles Alvarez Secord, MD– has disclosed that she receives grant/research supports from AbbVie, AstraZeneca, Clovis, Merck, and Oncoquest. 

Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron and Seagen. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers bureau for ONC Live and Curio Science. 

Shannon N. Westin, MD, MPH–has disclosed that she is a consultant for AstraZeneca, Clovis Oncology, GSK/Tesaro, and Novartis. She receives grant/research support from AstraZeneca, Clovis Oncology, GSK/Tesaro, and Novartis.

Content Reviewer: 
Justine Cooper Pickarski - has no relevant financial relationships to disclose in relation to the content of this activity.